276 related articles for article (PubMed ID: 24603487)
1. PTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemia.
Huang FF; Zhang L; Wu DS; Yuan XY; Yu YH; Zhao XL; Chen FP; Zeng H
PLoS One; 2014; 9(3):e88298. PubMed ID: 24603487
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia.
Huang FF; Wu DS; Zhang L; Yu YH; Yuan XY; Li WJ; Chen XP; Zhao XL; Chen FP; Zeng H
Cancer Lett; 2013 Aug; 336(1):96-105. PubMed ID: 23603434
[TBL] [Abstract][Full Text] [Related]
3. The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma.
Wang L; Lin N; Li Y
Oncol Rep; 2019 Mar; 41(3):1678-1690. PubMed ID: 30664164
[TBL] [Abstract][Full Text] [Related]
4. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.
Bleau AM; Hambardzumyan D; Ozawa T; Fomchenko EI; Huse JT; Brennan CW; Holland EC
Cell Stem Cell; 2009 Mar; 4(3):226-35. PubMed ID: 19265662
[TBL] [Abstract][Full Text] [Related]
5. The PTEN/PI3K/Akt pathway regulates stem-like cells in primary esophageal carcinoma cells.
Li H; Gao Q; Guo L; Lu SH
Cancer Biol Ther; 2011 Jun; 11(11):950-8. PubMed ID: 21467840
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
7. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression.
Nakanishi T; Shiozawa K; Hassel BA; Ross DD
Blood; 2006 Jul; 108(2):678-84. PubMed ID: 16543472
[TBL] [Abstract][Full Text] [Related]
8. The Critical Role of PTEN/PI3K/AKT Signaling Pathway in Shikonin-Induced Apoptosis and Proliferation Inhibition of Chronic Myeloid Leukemia.
Chen Y; Wang T; Du J; Li Y; Wang X; Zhou Y; Yu X; Fan W; Zhu Q; Tong X; Wang Y
Cell Physiol Biochem; 2018; 47(3):981-993. PubMed ID: 29843123
[TBL] [Abstract][Full Text] [Related]
9. Cigarette smoke promotes drug resistance and expansion of cancer stem cell-like side population.
An Y; Kiang A; Lopez JP; Kuo SZ; Yu MA; Abhold EL; Chen JS; Wang-Rodriguez J; Ongkeko WM
PLoS One; 2012; 7(11):e47919. PubMed ID: 23144836
[TBL] [Abstract][Full Text] [Related]
10. Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists.
To KK; Tomlinson B
Br J Pharmacol; 2013 Nov; 170(5):1137-51. PubMed ID: 24032744
[TBL] [Abstract][Full Text] [Related]
11. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
Cheng Z; Yang N; Liang W; Yan X; Li L; Pan L
Leuk Lymphoma; 2012 Jul; 53(7):1383-9. PubMed ID: 22185283
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.
Fischer B; Frei C; Moura U; Stahel R; Felley-Bosco E
Lung Cancer; 2012 Oct; 78(1):23-9. PubMed ID: 22857894
[TBL] [Abstract][Full Text] [Related]
13. PTEN's regulation of VEGF and VEGFR1 expression and its clinical significance in myeloid leukemia.
Zhiyong C; Wentong L; Xiaoyang Y; Ling P
Med Oncol; 2012 Jun; 29(2):1084-92. PubMed ID: 21360018
[TBL] [Abstract][Full Text] [Related]
14. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
[TBL] [Abstract][Full Text] [Related]
15. Functional screen analysis reveals miR-3142 as central regulator in chemoresistance and proliferation through activation of the PTEN-AKT pathway in CML.
Zhao L; Shan Y; Liu B; Li Y; Jia L
Cell Death Dis; 2017 May; 8(5):e2830. PubMed ID: 28542127
[TBL] [Abstract][Full Text] [Related]
16. PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia.
Kayabasi C; Yelken BO; Asik A; Okcanoglu TB; Sogutlu F; Gasimli R; Susluer SY; Saydam G; Avci CB; Gunduz C
Eur J Pharmacol; 2021 Nov; 910():174446. PubMed ID: 34461124
[TBL] [Abstract][Full Text] [Related]
17. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
18. Formaldehyde induces the apoptosis of BMCs of BALB/c mice via the PTEN/PI3K/Akt signal transduction pathway.
Yu G; Wang C; Song X; Liu S; Zhang Y; Fan L; Yang Y; Huang Y; Song J
Mol Med Rep; 2019 Jul; 20(1):341-349. PubMed ID: 31115571
[TBL] [Abstract][Full Text] [Related]
19. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K
Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
[TBL] [Abstract][Full Text] [Related]
20. TAL1 mediates imatinib-induced CML cell apoptosis via the PTEN/PI3K/AKT pathway.
Wu Y; Hu Y; Yu X; Zhang Y; Huang X; Chen S; Li Y; Zeng C
Biochem Biophys Res Commun; 2019 Nov; 519(2):234-239. PubMed ID: 31493871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
